Could a 3-Month Low-Dose blood thinner replace lifelong pills after heart procedure?

NCT ID NCT07575867

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with atrial fibrillation can safely stop taking long-term blood thinners after a procedure that closes off a part of the heart called the left atrial appendage. Participants will get a reduced dose of the blood thinner apixaban for just 3 months after the procedure, then stop all blood thinners. The goal is to see if this approach is better than staying on standard-dose blood thinners forever, by comparing rates of bleeding, stroke, and other complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Apixaban (reduced dose) and left atrial appendage closure device (Watchman FLX or Amplatzer Amulet)
What this could lead to
If successful, this could offer a way for people with atrial fibrillation to stop taking lifelong blood thinners after a heart procedure, reducing bleeding risk while still preventing strokes.
What could go wrong
This is an observational study, not a randomized trial, so results may be less reliable. The reduced-dose apixaban is only given for 3 months, and there is a risk of stroke or device complications if blood thinners are stopped too soon.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTICOAGULANTS / ADMINISTRATION & DOSAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Federal State Budgetary Institution National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthсare of the Russian Federation

    RECRUITING

    Moscow, 101990, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.